Lincoln Pharmaceuticals · NSE: LINCOLN · BSE: 531633
Q1 FY22 results · Apr–Jun 2021
Lincoln Pharmaceuticals reported revenue from operations of ₹119.74 crore (up 18.5% from Q1 FY21) and net profit of ₹17.38 crore (up 15.9% from Q1 FY21) for Q1 FY22 (Apr–Jun 2021), on a standalone basis.
| Item | Q1 FY22 | Q1 FY21 | YoY | Q4 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 119.74 | 101.03 | +18.5% | 77.54 | +54.4% |
| Other income | 2.32 | 1.97 | +17.5% | 2.51 | −7.4% |
| Total income | 122.06 | 103.01 | +18.5% | 80.05 | +52.5% |
| Profit before tax | 24.49 | 20.67 | +18.5% | 14.79 | +65.6% |
| Net profit for the period | 17.38 | 14.99 | +15.9% | 11.85 | +46.7% |
| EPS, basic (₹) | 8.69 | 7.50 | +15.9% | 5.92 | +46.8% |
| Net margin (%) | 14.5 | 14.8 | 15.3 |
Standalone
- Filed with BSE
- 10 Aug 2021, 15:38 IST
- Board meeting
- 10 Aug 2021
- Period
- 01 Apr 2021 to 30 Jun 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE